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Summary
This study develops a theory of drug discovery. The thesis will be elaborated that medical-
phannaceutical practice is an indispensable source offèedback to the drugdiscoveryprocess.
Às wil l be shown, the origin of new nredicines l ies in the interfàce of clevelopment in the
labrl 'atory and the application of therapy in dailv medical practice. -f l 're various methods of
gatheling kr.rorvledge about pharmacotherapy, and the mechanistns through which practice
contributes to the creation of nelv drugs wil l be cilr if ied.
In elabonting this thesis, a model is developed in order to describe tl 're drug discovery
process. The smrting point is the view tl.rat he development of medicines can be conceived
ofas a process ofrapprochenrent between knowledge pàtterns on the one hand ofdrugs and
on the other of diseases. The concept of profrle that forms a central part of comnrunicating
knowledge in the pharn"raceuticalsciences anclmedicine is taken as the basis of the presented
model. The epistemological view is developed that therapeutic cleveloprnent can be
regartled as the movement of patterns between proÍi les of drugls and diseases. Subsequently,
this vrelv is transfbrmed intri a set-theoretical modei of the drug discovery process.
The historicrlpart of this studv describes the evolution of the beta blockers and ti.re calcium
antegrinists. Ernphasis is on developnrents in the field clf angina pectoris roughly covering
theper ioc l  1950-1975. \ rar i< lus industr i i r lpro iectswereexaminet lagainst thebackgroundof
views on angina pectoris. heart failure ancl other crrrdiovascular diseases. The basic approach
consists of the conrparative analvsis of cieveloprnents in the Anglo-Arnerican and German
speaking rnedical worlcl with the emphasis or.r Brit ish ancl Atnerican meclicine on the one
hand ancl German medicine on the other. The cliffèrences described help to unravel
processes relevant to therapeutic progress. The methods used are interviews with
participants, l i terature-analysis ancl the assessrlent ofcitation patterns.
Chapter 1 starts fron-r t l.re contlict between the controiled ciinical trial and casual
experience. The wav through which the clinical trial has expelled casual experience as a tme
source of knowledue, ancl has structurecl dmg research, wil l be discussed. The comrnon view
underlving the clinical trial misrepesents the role of clinical medicine in rwo respects.
Firstlv, it gives clinical rnedicine a place somewhere in the rniddle of a l inear sequence of
events, with general practice as the final station. Secondly, it narrows-down the available
clinical methods for gathering information ranking these ancl putting the controlied clinical
trial at the top of the l ist. This might be correct when evaluation of knowledge is at stake,
but this is certainly not the case fionr the viewpoint of the generation of medical knowledge.
In chapter 2 the theoretical framework of the srudy is developed. In part 1 two sets of
philosophical terms usecl ir-r drug research, e.g. the distinctions "basic-applied" and
"rational-enrl. l ir ical" u,i l l  be discussed; with respect o the term "enrpirical" the terms of
serenclipiry ancl art rvil l  also be exanrinecl. In part 2 the concept of profi le is analysed while
in part 3 a set-theoretical definit ion oltthis concept and a set-theorerical model of drug
discovery are presentecl.
In chapter 3 the early histori. 'of the beta blockers wil l be sketched in order to i l lustrate the
rvav experimental nd clinical characteristics of (new) clrugs are clarif ied; this also forms the




In chapter 4 some industrial prcjects in tl.re bcta blocker field are described. The projects
at Lnperiai (lhemicallndustries (IOI) in the United Kingdurn and AB Hrissle in Sweden are
examined in detail because both were ar t lre Íiontiers of bio-rnedicine. Th e I(lI tearn created
famous drugs such as pronetlralol, propranolol, practolol and atenolol, eacl'r of them starting
a new episode in the beta blocker field. Because of the emphasis on angir.ra pectoris, the
development of atenolol in the context of antihypertensive therapy has been excluded. The
Hàssle teanr is described because of its difÍèrent background compared with ICI, the ckrse
cooperation with academic and clinical scientists, t l 're creation of irnport:rnt concepts in the
field, and the development of irnportant drugs, i.e. alprer.rolol and n'reto;lrolol.
In chapter 5 the curious historv of veraparnil is ciescribed. Developed as a coronary
vas<idilator for anti-anginal treattnent, the drug was recognized as a beta blocking
compound but after heated debate rejected as such. Being a dying drug in the treatnrent of
angina pectoris, its resurrccrion u,as inrpressivc when a novel f i/pe of action rvas unravelecl.
l[-he elucidation of verapamil as a calciun-r lntagonist has been acknowledgecl as the result
of ex;lerimental work of Fleckenstein. For this reason the way Fleckenstein and co-workers
disentangled the mechanism of action of verapan.ri l wil l be described. Subsequentlv a
scientometric analysis is perfonned to investigate huu. the concept of calcirirn antagonisnr
l.ras been accepted by the medical conrnruniry. The "logic" of drug and diselse proftles rvil l
be applied to highlight some events in the history of verapamil.
Chapter 6 discusses the developnrent of Anglo-Anerican vieu,s :rlrout angina pcct(Jris.
Though it covers roughlv the periorl 1950 - 1980, ernpl.rasis is on rna jor shrfis occurring in
late 1950s and earlv 1970s. It describes how the syndronre of anplina of ell irrt becarne a
dorninant cateÉlory in clinical taxononrl, of angina pecroris, and horv it sul>setlrentlv
declinecl, creating room for new concepts. In this way the conclusion of the preceding
chapter, i.e. that changes irr views of a ngina pectoris were relevant o verapam il 's revivll, wil l
be elaborated.
Chapter  7 concerns the c leveloprnent  of  the beta b locker  pro ject  i r t  Boehr inger  Inge lheim
in ()ermany. The Boehringer team possessed prornising conrpouncls at an early stage but
was not  able to achieve a c lominant  pt is i t ion in  the f le ld.  Frorn th is  v iervpoint  the pro ject
might be considerecl a failure.It is a privilege to be perrnitted to describe this project beciruse
access to insicle material on 1àilecl projects in pharmaceutical-industrial research is sekiont
grantecl. However, failure delivers a rnirror f l ir the tl iscontinuitva nd irleg'ularin'ofsciendflc
research. Putting the project in the context of Germirn medicine it is shriwn that rcse',rrch
at Boehringer was victinr of meclical views which appeared to be infèrti le soil Íbr the
development of the beta blockers.
In part 1 of chapter 7 the Clernran nredical views on coron'Jr\. 'vasodilators in anti-anginaI
therapy, heart failure and rtngina pectoris are discr.rssecl. \\r ith respect to the viervs of
coronary vasodilators and helrt failure the viervs are contrasted lvith Ang)o-Anterican
concepts. Regarding the (]errnan viervs of anginl pectoris, the contr' lsr with views in the
Brit ish and Arnerican rnedical world descriLred in chaoter 6. be cornes clear.
Chapter 8 cliscusses three issr"res. Firstlv, the search process fbr drugs wil l be reconsiclered
in the l ight  of  the ins ights achieved and wi l l  be re lated to current  concepts a l rout  rar ional
drug clesign and screening. Secondll ' , tu,o points of crit icisrn relating to the model wil l be
raised, i.e. the episternolclgical status of the concept of profi le; and the issue to u,l 'rar exrent
180
knowledge is explicable. Thirdly, the way rneclical-pharmaceurical pracice conrribures to
drug discovery wil l be sysremarically analyzed.
In chapter 9 the role of practice wil l be reconsidered in the context of the increasins
attention towards the srudy of bio-rnolecular processes. In crit icizing this increasingl!
popular view, the basic claim of t l.r is thesis, i.e. that the exchange of iniormation berween
biological sciences and medical-pharnraceutical practice is crucial to the discovery process,
wil l be elaborated anew.
